111 related articles for article (PubMed ID: 9206182)
1. [Clinicopathological evaluation on ovarian serous borderline tumours and their implants].
Guo L; Lian L; Liu T
Zhonghua Fu Chan Ke Za Zhi; 1996 May; 31(5):287-90. PubMed ID: 9206182
[TBL] [Abstract][Full Text] [Related]
2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
3. [Proliferating cell nuclear antigen (PCNA) in ovarian carcinoma and its relation to lymph node metastasis and prognosis].
Wu X; Zhang Z; Cai S
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):68-70. PubMed ID: 10921065
[TBL] [Abstract][Full Text] [Related]
4. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
7. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
8. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
11. Morphometry and digital AgNOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours.
Stemberger-Papić S; Stanković T; Vrdoljak-Mozetic D; Versa-Ostojić D; Krasević M; Stifter S; Audy-Jurković S
Cytopathology; 2006 Dec; 17(6):382-9. PubMed ID: 17168922
[TBL] [Abstract][Full Text] [Related]
12. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
13. Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours.
Stewart CJ; Brennan BA; Crook ML; Russell P
Histopathology; 2007 Sep; 51(3):313-21. PubMed ID: 17727474
[TBL] [Abstract][Full Text] [Related]
14. Glomeruloid peritoneal implants in ovarian serous borderline tumours--distinction between invasive and non-invasive implants and pathogenesis.
Lee ES; Leong AS; Kim IS; Kim YS; Lee JH; Cho HY
Histopathology; 2009 Nov; 55(5):505-13. PubMed ID: 19912356
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
16. Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern.
Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
BJOG; 2009 May; 116(6):860-2. PubMed ID: 19432576
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
Vereczkey I; Tóth E; Orosz Z
Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
[TBL] [Abstract][Full Text] [Related]
18. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
Ann Surg Oncol; 2008 Dec; 15(12):3561-6. PubMed ID: 18820973
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
[TBL] [Abstract][Full Text] [Related]
20. Characteristic features of ovarian borderline tumors with invasive implant.
Ohta T; Ohmichi M; Hayasaka T; Saitoh M; Kojimahara T; Kawagoe J; Nakahara K; Motoyama T; Kurachi H
Arch Gynecol Obstet; 2005 Oct; 272(4):278-82. PubMed ID: 16012777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]